Centene Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Centene wird ein jährliches Gewinn- und Umsatzwachstum von 4.9% bzw. 5.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.2% betragen.
Wichtige Informationen
4.9%
Wachstumsrate der Gewinne
9.7%
EPS-Wachstumsrate
Healthcare Gewinnwachstum | 21.1% |
Wachstumsrate der Einnahmen | 5.7% |
Zukünftige Eigenkapitalrendite | 13.2% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 14 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024
Oct 22Centene Corporation (NYSE:CNC) Screens Well But There Might Be A Catch
Oct 14Should You Be Adding Centene (NYSE:CNC) To Your Watchlist Today?
Sep 26Centene (NYSE:CNC) Has Some Way To Go To Become A Multi-Bagger
Sep 08Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly
Aug 20Centene Corporation: Strategic Market Position Amid Favorable Trends, Buy
Aug 20Centene (NYSE:CNC) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 02Here's Why We Think Centene (NYSE:CNC) Is Well Worth Watching
Jun 22A Piece Of The Puzzle Missing From Centene Corporation's (NYSE:CNC) Share Price
Jun 04Returns At Centene (NYSE:CNC) Appear To Be Weighed Down
May 14These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well
Apr 26Centene Corporation Still An Opportunity With An A-Grade Valuation
Mar 31If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity
Mar 15Market Still Lacking Some Conviction On Centene Corporation (NYSE:CNC)
Feb 08Centene: Stay Defensive Amid Economic Uncertainty With This Low-Beta Bargain
Jan 22Is Centene (NYSE:CNC) Using Too Much Debt?
Jan 21Centene: Overlooked Healthcare Giant
Nov 21Does Centene (NYSE:CNC) Deserve A Spot On Your Watchlist?
Nov 10Centene: Solid Performance With Positive Outlook, But Limited Upside Potential
Oct 26These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well
Oct 22Decoding Centene: Why I Think It's Undervalued
Oct 10If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity
Jul 31Centene: Results Impress But Buyers Aren't Swarming Yet
Jul 27Centene (NYSE:CNC) Has A Pretty Healthy Balance Sheet
Jul 12Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly
Apr 10Centene Non-GAAP EPS of $0.86 beats by $0.02, revenue of $35.56B beats by $190M
Feb 07With EPS Growth And More, Centene (NYSE:CNC) Makes An Interesting Case
Jan 27Centene (NYSE:CNC) Seems To Use Debt Rather Sparingly
Dec 27Centene: Once Again, With Quality, Now A 'Buy'
Dec 23Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid
Dec 14An Intrinsic Calculation For Centene Corporation (NYSE:CNC) Suggests It's 50% Undervalued
Nov 11Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 172,544 | 3,430 | 4,070 | 5,299 | 13 |
12/31/2025 | 165,251 | 3,016 | 3,827 | 4,953 | 15 |
12/31/2024 | 161,215 | 3,110 | 1,888 | 2,524 | 12 |
9/30/2024 | 146,204 | 3,067 | 245 | 958 | N/A |
6/30/2024 | 144,064 | 2,823 | 2,261 | 2,957 | N/A |
3/31/2024 | 142,800 | 2,735 | 2,603 | 3,328 | N/A |
12/31/2023 | 141,266 | 2,702 | 7,254 | 8,053 | N/A |
9/30/2023 | 139,364 | 2,444 | 5,451 | 6,260 | N/A |
6/30/2023 | 138,111 | 2,713 | 7,651 | 8,571 | N/A |
3/31/2023 | 136,941 | 1,483 | 8,392 | 9,379 | N/A |
12/31/2022 | 135,999 | 1,202 | 5,257 | 6,261 | N/A |
9/30/2022 | 132,756 | 2,014 | 7,493 | 8,512 | N/A |
6/30/2022 | 129,228 | 1,860 | 5,985 | 6,982 | N/A |
3/31/2022 | 124,181 | 1,497 | 4,348 | 5,313 | N/A |
12/31/2021 | 118,573 | 1,347 | 3,295 | 4,205 | N/A |
9/30/2021 | 114,130 | 736 | 5,643 | 6,511 | N/A |
6/30/2021 | 111,284 | 720 | 2,863 | 3,757 | N/A |
3/31/2021 | 108,158 | 2,461 | 4,907 | 5,786 | N/A |
12/31/2020 | 104,280 | 1,808 | 4,634 | 5,503 | N/A |
9/30/2020 | 95,764 | 2,029 | 1,008 | 1,871 | N/A |
6/30/2020 | 86,523 | 1,556 | 1,918 | 2,724 | N/A |
3/31/2020 | 78,105 | 845 | -804 | -73 | N/A |
12/31/2019 | 70,807 | 1,321 | 753 | 1,483 | N/A |
9/30/2019 | 68,385 | 1,353 | 784 | 1,500 | N/A |
6/30/2019 | 65,507 | 1,277 | 1,498 | 2,147 | N/A |
3/31/2019 | 61,028 | 1,082 | 71 | 704 | N/A |
12/31/2018 | 56,688 | 900 | 559 | 1,234 | N/A |
9/30/2018 | 52,618 | 889 | 1,708 | 2,318 | N/A |
6/30/2018 | 48,655 | 1,075 | N/A | 1,867 | N/A |
3/31/2018 | 47,201 | 1,029 | N/A | 2,087 | N/A |
12/31/2017 | 45,810 | 828 | N/A | 1,489 | N/A |
9/30/2017 | 44,870 | 853 | N/A | 2,631 | N/A |
6/30/2017 | 43,646 | 796 | N/A | 3,016 | N/A |
3/31/2017 | 42,468 | 713 | N/A | 2,903 | N/A |
12/31/2016 | 37,693 | 562 | N/A | 1,851 | N/A |
9/30/2016 | 32,839 | 416 | N/A | 460 | N/A |
6/30/2016 | 28,062 | 360 | N/A | 40 | N/A |
3/31/2016 | 22,948 | 277 | N/A | 809 | N/A |
12/31/2015 | 21,292 | 356 | N/A | 658 | N/A |
9/30/2015 | 19,854 | 350 | N/A | 827 | N/A |
6/30/2015 | 18,548 | 339 | N/A | 1,206 | N/A |
3/31/2015 | 17,102 | 298 | N/A | 1,016 | N/A |
12/31/2014 | 15,689 | 268 | N/A | 1,223 | N/A |
9/30/2014 | 14,134 | 210 | N/A | 1,023 | N/A |
6/30/2014 | 12,700 | 179 | N/A | 713 | N/A |
3/31/2014 | 11,475 | 172 | N/A | 591 | N/A |
12/31/2013 | 10,544 | 161 | N/A | 382 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CNCDas prognostizierte Gewinnwachstum (4.9% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: CNCDie Erträge des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).
Hohe Wachstumserträge: CNCDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: CNCDie Einnahmen des Unternehmens (5.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: CNCDie Einnahmen des Unternehmens (5.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: CNCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.2%).